ClinicalTrials.Veeva

Menu

Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit

Wyeth logo

Wyeth

Status

Completed

Conditions

Gram-Positive Bacterial Infections

Treatments

Drug: Piperacillin/tazobactam and other β-lactam/β-lactamase

Study type

Observational

Funder types

Industry

Identifiers

NCT00167960
0910X-101525

Details and patient eligibility

About

To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients admitted to or transferred to the SICU.
  • Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU.
  • Provide written informed consent

Exclusion criteria

  • Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors.
  • Females who are pregnant and breast feeding
  • Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours.
  • Those who have already been participating other clinical study related with antibiotics.

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems